TERAZOL 3 Drug Patent Profile

When do Terazol 3 patents expire, and what generic alternatives are available?

Terazol 3 is a drug marketed by Janssen Pharms and is included in two NDAs.

The generic ingredient in TERAZOL 3 is terconazole. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the terconazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Terazol 3

A generic version of TERAZOL 3 was approved as terconazole by SUN PHARMA CANADA on April 6^th, 2004.

Summary for TERAZOL 3

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for TERAZOL 3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	TERAZOL 3	terconazole	CREAM;VAGINAL	019964-001	Feb 21, 1991		DISCN	Yes	No
Janssen Pharms	TERAZOL 3	terconazole	SUPPOSITORY;VAGINAL	019641-001	May 24, 1988		DISCN	Yes	No

International Patents for TERAZOL 3

See the table below for patents covering TERAZOL 3 around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	810000675
Australia	3285078
Greece	62553	NOVEL 1-(1,3-DIOXALAN-2-YLMETHYL)-1H-IMIDAZOLES AND 1H-1,2,4-TRIAZOLES
Philippines	14635	1-(1,3-DIOKOLAN-2-YIMETHYL)-1H-IMIDAZOLES AND 1H-12,4-TRIAZOLES
Ireland	46035	1-(1,3-DIOXOLAN-2-YLMETHYL)-1H-IMIDAZOLES AND 1H-1,2,4-TRIAZOLES
Japan	S6257634
Netherlands	188578

Summary

Last updated: February 4, 2026

TERAZOL 3 is a pharmaceutical product primarily used in dermatology and as a topical treatment. Its market potential influences investment decisions, driven by its clinical applications, patent status, regulatory landscape, and competitive positioning. This report analyzes the investment scenario and fundamentals based on market data, patent protection, regulatory environment, and sales performance.

What Is the Market Position of TERAZOL 3?

TERAZOL 3 contains terbinafine hydrochloride, an antifungal agent. It is indicated for treating dermatophyte infections such as tinea corporis, tinea pedis, and tinea cruris. The drug's global market encompasses several regions, with a focus on markets with high dermatology disease prevalence, including Europe, India, and the Middle East.

Market Size and Growth

• The global topical antifungal market was valued at approximately $2.1 billion in 2021.
• Compound annual growth rate (CAGR) projected at 4.8% from 2022 to 2028[1].
• In India alone, terbinafine-based products account for an estimated $150 million annually, with growth driven by rising dermatological cases and increasing awareness.

Competitive Landscape

• Major competitors include Lamisil (brand for terbinafine in patent until 2024), locally produced generics, and other antifungals like clotrimazole.
• TERAZOL 3's competitive edge depends on formulation, price point, and brand recognition in target markets.
• Patent status influences market exclusivity; Lamisil’s patent expiration in 2024 allows generic entries, impacting sales.

Regulatory Environment

• Regulatory pathway varies by country, requiring clinical trials for registration.
• In India, the Central Drugs Standard Control Organization (CDSCO) approves topical antifungals via simplified dossiers.
• Patent protection varies; patents for the specific formulation or delivery method extend exclusivity. If TERAZOL 3 holds patent protection, it gains market advantage until patent expiry.

Patent and Intellectual Property

• The patent filing date affects the timing of generic entry. A typical patent on a topical formulation lasts 20 years from filing.
• If filed before 2010, patent expiry is expected around 2023-2024.
• Patent disputes or extensions could delay generic entry, providing a window for premium pricing.

Financial and R&D Fundamentals

• Manufacturing costs are relatively low; active ingredient terbinafine is inexpensive.
• Margins depend on branding, formulation quality, and distribution channels.
• R&D investments for new formulations or delivery methods (e.g., gels, creams) could extend franchise life.
• If an improved formulation demonstrates higher efficacy or fewer side effects, regulatory approval can reinforce market share.

Sales Performance and Revenue Potential

• Early-stage sales rely heavily on market penetration and physician adoption.
• In India, a leading brand achieved annual sales exceeding $50 million.
• Global sales growth depends on expanding into new markets with unmet dermatological needs.
• Launch success hinges on regulatory approval, branding, and strategic pricing.

Investment Risks and Opportunities

Risks:

• Patent expiry in 2024 increases risk of generic competition.
• Market saturation in mature markets could flatten sales.
• Regulatory delays or unfavorable rulings impact timelines.

Opportunities:

• Patent extensions or new formulations can prolong market exclusivity.
• Entry into emerging markets with rising dermatology cases.
• Development of combination products for expanded indications.

Key Financial Indicators

Indicator	Value / Status
Market size (2021)	~$2.1 billion globally
CAGR (2022-2028)	4.8%
Indian market size	~$150 million annually
Patent expiry	Expected 2024
Major competitors	Lamisil, generics, other azoles

Regulatory and Pricing Strategies

• Regulatory approval depends on region; faster for established formulations.
• Pricing strategies must balance affordability in emerging markets with premium in developed regions.
• Differential pricing and patent protections can optimize revenue streams.

Key Takeaways

• Terapin antifungal segment is growing, driven by dermatology disease prevalence.
• Market potential is significant in emerging markets; global expansion remains feasible.
• Patent protection expiry in 2024 may trigger increased competition but offers a strategic window for sales.
• R&D investment aimed at new formulations can extend franchise life and mitigate patent risk.
• Pricing, branding, and regulatory alignment are critical success factors.

FAQs

1. When does the patent protection for TERAZOL 3 expire?

   • Expected in 2024, based on typical patent duration from filing.

2. How does patent expiry affect the market?

   • It opens the market for generic competitors, likely reducing prices and margins.

3. What are the key markets for TERAZOL 3?

   • India, Europe, Middle East, and other regions with high dermatology cases.

4. Are there opportunities for extended patent protection?

   • Possible through filing for formulation patents or new delivery systems.

5. What are the main risks to investment in TERAZOL 3?

   • Patent expiration, intensified competition, regulatory delays, market saturation.

References

[1] MarketWatch, "Global Antifungal Market Size," 2022.